References
- Fanta CH. Asthma. N Eng J Med 2009;360:1002–1014
- Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Critical Care Med 2004;170:836–844
- Partridge MR, van der Molen T, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulmon Med 2006;6:13
- Peters SP, Jones CA, Haselkorn T, Mink DR, Valacer DJ, Weiss ST. Real-world Evaluation of Asthma Control and Treatment (REACT): findings from a national Web-based survey. J Allergy Clin Immunol 2007;119:1454–1461
- National Heart L, and Blood Institute. Expert Panel Report 3: Guidelines for the Diagnosis and Treatment of Asthma. National Heart L, and Blood Institute, editor. Bethesda, Maryland, USA 2007
- From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014. Available from: http://www.ginasthma.org/. Accessed December 15, 2014
- Bousquet J, Bousquet PJ, Godard P, Daures JP. The public health implications of asthma. Bull World Health Organ 2005;83:548–554
- Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302–308
- Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006;2:CD003559
- https://www.census.gov/geo/maps-data/maps/pdfs/reference/us_regdiv.pdf [last accessed 12 Nov 2014]
- Sullivan PW, Smith KL, Ghushchyan VH, Globe DR, Lin SL, Globe G. Asthma in USA: its impact on health-related quality of life. J Asthma 2013;50:891–899
- Sullivan PW, Slejko JF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D Scores for the United Kingdom. Med Decis Making 2011;31:800–804
- Sullivan PW, Ghushchyan VH, Slejko JF, Belozeroff V, Globe DR, Lin SL. The burden of adult asthma in the United States: evidence from the Medical Expenditure Panel Survey. J Allergy Clin Immunol 2011;127:363–369
- Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, Ohta K, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31:143–178
- Broder MS, Zazzali JL, Chang E, Yegin A. Concomitant asthma medication use by patients receiving omalizumab 2003–2008. J Asthma: Official J Assoc Care Asthma 2011;48:1058–1062
- Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P. Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma. Ann Allergy Asthma Immunol: Official Publ Am College Allergy Asthma Immunol 2012;109:59–64
- Regnier SA. How does drug coverage vary by insurance type? Analysis of argue formularies in the United States. Am J Manag Care 2014;20:322–331
- Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J, FitzGerald JM. Economic burden of asthma: a systematic review. BMC Pulmon Med 2009;9:24
- Jang J, Gary Chan KC, Huang H, Sullivan SD. Trends in cost and outcomes among adult and pediatric patients with asthma: 2000–2009. Ann Allergy Asthma Immun: Official Publ Am College Allergy Asthma Immunol 2013;111:516–522
- Stempel DA, Hedblom EC, Durcanin-Robbins JF, Sturm LL. Use of a pharmacy and medical claims database to document cost centers for 1993 annual asthma expenditures. Arch Fam Med 1996;5:36–40